Arbutus Biopharma Corporation, FKA Protiva Biotherapeutics, Inc., v. Modernatx, Inc., FKA Moderna Therapeutics, Inc. No. 2020-1183 (Fed. Cir. April 11, 2023)

Arbutus Biopharma Corp. v. Modernatx, Inc. addresses the legal standard for inherent anticipation. The case involves the ’127 patent, which claims stable nucleic acid-lipid particles and methods of making and delivering them. The patent seeks to improve the efficiency of introducing nucleic acids into cells.

Posta un commento